Priority 19 from the Psoriasis PSP

UNCERTAINTY: What is the best and most cost-effective way of monitoring an oral or biological therapy for psoriasis e.g. clinical review, blood tests and measurement of medicine/antibodies levels? (JLA PSP Priority 19)
Overall ranking 19
JLA question ID 0072/19
Explanatory note Not available for this PSP

Kromer, 2018 Some evidence for cost-effectiveness of biological therapy (ie high-cost treatment / high efficacy) presented.  Several studies reviewed were sponsored by pharma.  Some comparative data presented but future research recommended. 

Health Research Classification System category Skin
Extra information provided by this PSP
Original uncertainty examples What is the safe/optimal monitoring strategy for patients established on biologic therapy?
Submitted by 6 uncertainties were submitted around this question
PSP information
PSP unique ID 0072
PSP name Psoriasis
Total number of uncertainties identified by this PSP. 55  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 17 September 2018